ERAP1 activity modulates the immunopeptidome but also affects the proteome, metabolism and stress responses in cancer cells.

A preprint abstract from biorxiv.org discusses the role of Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) in cancer cells. ERAP1 metabolizes peptides in the endoplasmic reticulum and influences the peptide repertoire available for binding to Major Histocompatibility Complex Class I molecules. The study used genetic silencing and an ERAP1 inhibitor to investigate changes in the immunopeptidome and proteome of melanoma and leukemia cell lines. The findings suggest that modulation of ERAP1 activity can lead to unique immunopeptidomes and also induce changes in the cellular proteome and metabolic state, potentially affecting tumor cells. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]